IDH1 mutations have been recurrently reported in low-grade glioma, glioblastoma multiforme (1), acute myeloid leukemia (AML) (2), cholangiocarcinoma (3), chondrosarcoma, and also melanoma (4,5). This evidence concerns the gene IDH1 and central nervous system cancer.